News

Ceres Nanosciences Receives $1.4M From NIH RADx Initiative to Add Five Additional Wastewater-Based Epidemiology Centers of Excellence

MANASSAS, Virginia – Ceres Nanosciences (Ceres), a privately held company that makes innovative products to improve life science research and diagnostic testing, is announcing today that it is expanding the network of wastewater-based epidemiology centers of excellence that was established with support from the National Institutes of Health (NIH) RADx® initiative. With a new $1.4 million award from the NIH, Ceres will identify and establish five additional centers of excellence to join the existing network of 16 sites comprising public health labs, non-profit labs, university labs, and commercial testing labs in 14 states. Ceres also will support the verification of SARS-CoV-2 genotyping from wastewater samples and the addition of this capacity to a subset of the centers of excellence.

coemap.png

Each new center of excellence will receive the materials and on-site training to implement an automated Nanotrap® particle protocol, which enables same-day delivery of wastewater testing results for over 100 samples per day. Extracted nucleic acids from this automated protocol are compatible with multiple nucleic acid detection methods, including reverse transcription-quantitative polymerase chain reaction, reverse transcription-droplet digital PCR, reverse transcription digital PCR, and genomic sequencing.

“The United States is demonstrating global leadership in wastewater-based epidemiology through public-private partnerships like this,” said Robbie Barbero, Ph.D., Chief Business Officer at Ceres Nanosciences. “I am very proud that Ceres has once again been recognized by the U.S. government for our innovative technology and collaborative approach to advancing this field.”

Centers are expected to share data and results with local, state, Tribal, and Federal public health decision makers and to participate in the CDC National Wastewater Surveillance System. Each new center will be selected based on its ability to utilize the expanded testing capacity to extend services into underserved and underprivileged communities and to balance the geographic reach of the network.

Read more here

Recent News

07/01/2025

ISOThrive Announces Promising Phase 2 Interim Data for Novel Heartburn Treatment and Appoints Pharma Veteran Mike Walther as Chief Strategy Officer

ISOThrive Inc., a clinical-stage biopharmaceutical company, announced interim results from a Phase 2 study of its lead candidate, ISOT-101, for treatment of Non-Erosive Reflux Disease (NERD). The data showed positive trends in addressing heartburn frequency and symptom severity among proton pump inhibitor (PPI) partial-responders (PR), a patient population with major unmet medical need. These positive

07/01/2025

Gary Lowenthal Joins Focused Ultrasound Foundation’s Council

The Focused Ultrasound Foundation is pleased to welcome Gary Lowenthal to its Council, a dedicated group of goodwill ambassadors who work closely with the Board of Directors and staff to provide advice and assist with raising funds and building awareness. Mr. Lowenthal is a retired educator, entrepreneur, and executive with a career spanning education, international service,

06/25/2025

Liquet Medical Closes Oversubscribed Seed Round to Launch Pilot Study Evaluating Real-Time Hemodynamic Monitoring

Liquet Medical, a clinical-stage medical device company developing the Versus™ Catheter — a first-of-its-kind dual-tipped catheter system cleared by the FDA for controlled and selective infusion of fluids into the pulmonary vasculature and hemodynamic monitoring — announced the successful and oversubscribed close of its Seed funding round, which officially closed in May 2025. The capital